Pharmaceuticals Market Research Reports & Industry Analysis
Pharmaceuticals Industry Research & Market Reports
-
Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products
... filters) that prevent occurrence of nosocomial infections. Within each type of treatment, regional analyses will focus on the Americas (i.e. Canada, the U.S., Mexico, Central America and South America), EMRA (i.e. Europe, the Middle East, ... Read More
-
Indonesia Pharmaceuticals & Healthcare Q4 2018
... health insurance scheme (JKN), further expansion will be hampered by deficit,investment shortages and uneven levels of healthcare access across the country. Additionally, for the pharmaceutical industry, theJKN's positive impact on growth is likely to wane ... Read More
-
Kyrgyzstan Pharmaceuticals & Healthcare Q4 2018
... Kyrgyzstan's small and highly ruralised population will continue to restrict opportunities for multinational pharmaceuticalfirms. Key barriers for access to modern medicines include a lack of spending power and challenges in supply and distributionacross the country. Read More
-
Antipsychotic Drugs: Technologies and Global Markets
... a detailed analysis of the competitive environment, regulatory scenario, technological advancements, patent analysis, pipeline analysis, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2023, as well as market ... Read More
-
Puerto Rico Pharmaceuticals & Healthcare Q4 2018
... targeting drug spending rise and the US administration maintainsa stringent stance towards securing federal healthcare funds for Puerto Rico. Economic challenges and outward migration of labourwill further raise risks to the island's attractiveness to manufacturers, ... Read More
-
Tanzania Pharmaceuticals & Healthcare Q4 2018
... limited by low per capita spending on medicines andan underdeveloped healthcare sector. Whilst demand for medicine will increase over the long-term, driven by the country’s rapidlyexpanding population and high disease burden, we expect that Tanzania's ... Read More
-
Spain Pharmaceuticals & Healthcare Q4 2018
... of the generic drug sector and the government’s continuedfocus on cost-containment measures targeting prescription drug expenditure. These trends, along with a subdued economicoutlook, make Spain one of the more challenging markets in Western Europe for ... Read More
-
Morocco Pharmaceuticals & Healthcare Q4 2018
... treatments. Although the government'scommitment to improving healthcare via the expansion of health insurance coverage will be a significant factor for future medicinesales growth, we believe generics drugmakers will be the main beneficiaries as the state ... Read More
-
Philippines Pharmaceuticals & Healthcare Q4 2018
... prominent theme within the Philippines pharmaceutical market, repressing drugmakersales growth. With the expansion of universal health coverage, these pressures will increase, offsetting the positive impact ofincreased access to services and a reduction in out-of-pocket payments. Read More
-
Canada Pharmaceuticals & Healthcare Q4 2018
... environment maintains Canada's attractiveness for drugmakers,including opportunities to establish manufacturing facilities. However, drugmakers will be challenged by the increasing use ofaggressive pricing policies, with historically high generics prices increasingly becoming a target for cost-containment measures. Read More
-
Colombia Pharmaceuticals & Healthcare Q4 2018
... Colombia. However, despite price control measures and a weak intellectual property environment, healthcarereforms and the rising burden of chronic diseases will facilitate the rising demand for medicines – boosting the consumption ofmedicines in volume terms. Read More
-
Laos Pharmaceuticals & Healthcare Q4 2018
... improving the population’s access to healthcare, the still underdevelopedhealth system will limit drugmaker opportunities. While the rising burden of communicable diseases and the gradual rolling-out ofuniversal healthcare will present improved commercial opportunities for drugmakers over ... Read More
-
Peru Pharmaceuticals & Healthcare Q4 2018
... to medicine, butwith limited resources available to the government, cost containment measures will pose challenges to innovative drugmakers.However, the improved but hostile political environment, following the resignation of the formal president poses upside risks toinvestment. Read More
-
Russia Pharmaceuticals & Healthcare Q4 2018
... policy continuity will lead toincreased investment in localised drug production in the market, although this will remain heavily weighted towards the genericmedicines sector given the continued regulatory issues and market access barriers for innovative drugmakers. Read More
-
Saudi Arabia Pharmaceuticals & Healthcare Q4 2018
... 2030’ encouraging the expansion of manufacturingagreements in the country. While regulatory risks remain prevalent, and recent disputes with European players highlightchallenges of doing business in the country, positive market drivers will ensure robust long-term opportunities ... Read More
-
Ethiopia Pharmaceuticals & Healthcare Q4 2018
... government is strongly committed to improvingthe operating environment to attract foreign investment, particularly from China, which combined with a budding manufacturingsector bodes well for foreign drugmaker appetite. Over the near-term, multinational drugmaker investment in the ... Read More
-
Iran Pharmaceuticals & Healthcare Q4 2018
... and has triggered intense negotiations surrounding theIslamic Republic's future ability to integrate into the global economy. Although the supply of medical equipment and devices willsteadily decline, Iran's healthily domestic drug production capabilities and limited exposure ... Read More
-
Bahrain Pharmaceuticals & Healthcare Q4 2018
... preference of branded medicine over generic drugs. Furthermore, thegradual improvement of intellectual property protection and regulatory enforcement coupled with the establishment of acompulsory national health insurance scheme will provide greater investment opportunities for multinational drugmakers ... Read More
-
Estonia Pharmaceuticals & Healthcare Q4 2018
... patients with high drug costs. Over the long-term,patented medicine sales will be supported by an ageing demographic and the high prevalence of cardiovascular disease andcancers. However, multinational drugmakers’ interest in the market will remain limited ... Read More
-
Global and Chinese Cooling Paste Industry, 2018 Market Research Report
... market. The report provides key statistics on the market status of the Cooling Paste manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Firstly, the report provides ... Read More
-
Global and Chinese Carsickness Paste Industry, 2018 Market Research Report
... market. The report provides key statistics on the market status of the Carsickness Paste manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Firstly, the report provides ... Read More
-
Global and Chinese Gynecology Obstetric Operating Table Industry, 2018 Market Research Report
... focus on the Chinese market. The report provides key statistics on the market status of the Gynecology Obstetric Operating Table manufacturers and is a valuable source of guidance and direction for companies and individuals interested ... Read More
-
Global and Chinese Dysmenorrhea Paste Industry, 2018 Market Research Report
... market. The report provides key statistics on the market status of the Dysmenorrhea Paste manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Firstly, the report provides ... Read More
-
China Biologic Products Inc (CBPO) - Financial and Strategic SWOT Analysis Review
... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More
-
IOL Chemicals and Pharmaceuticals Ltd (IOLCP) - Financial and Strategic SWOT Analysis Review
... bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you ... Read More
